Low Dose Atazanavir/r Versus Standard Dose Atazanavir/r (LASA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

ATV/r 200/100 mg will be judged to be non-inferior to ATV 300/100mg if the lower limit of the 95% confidence interval for the difference in proportion of patients with virological response between the two groups does not exceed -10%

Secondary Outcome Measures
:

viral load [ Time Frame: DEc. 2013 ]

A secondary efficacy analysis will explore the impact of changing the lower limit of detection of viral load to <50 copies/mL

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.